Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.81 |
| ▸ | CCNE2 | O96020 | 14/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.81 |
| ▸ | CDK2 | P24941 | 14/20 | 0.81 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | ATR | Q13535 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034893 | 0.92 | GSK3B (0.86) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034107 | 0.89 | GSK3B (0.97) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6035397 | 0.89 | GSK3B (0.76) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034060 | 0.89 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034462 | 0.89 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6598347 | 0.88 | GSK3B (0.84) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034043 | 0.87 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034774 | 0.87 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034595 | 0.87 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6598075 | 0.83 | GSK3B (0.57) | GSK3BCCNE2CCNE1CDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |